

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: B. COHEN et al. :  
APPLICATION SERIAL NO.: 10/775,444 : Examiner: Tungaturthi, P.  
FILING DATE: February 10, 2004 : Group Art Unit: 1643  
TITLE: USES OF ANTI-INSULIN-LIKE GROWTH :  
FACTOR I RECEPTOR ANTIBODIES

Mail Stop PETITION  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**PETITION FOR REVIVAL OF UNINTENTIONALLY ABANDONED APPLICATION  
UNDER 37 CFR § 1.137(b)**

Sir:

The above-identified application became abandoned due to Applicant's unintentional failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. Petitioner hereby requests revival of the application as an unintentionally abandoned application pursuant to 37 CFR §1.137(b).

Pursuant to §1.137(b)(1), Petitioner is filing concurrently herewith a response to the outstanding Office Action to advance the prosecution of the application.

Since this utility application was filed on or after June 8, 1995, no terminal disclaimer is required.

Finally, Applicants hereby state that the entire delay in filing the required reply from the due date for the reply until the filing of this grantable petition under 37 CFR § 1.137(b) was unintentional.

The petition fee for other than a small entity is \$1500.00 under 37 CFR § 1.17(m). Authorization is hereby provided to charge the amount of the fee under 37 C.F.R. §1.17(m), as

Serial No. 10/775.444

PC25232A

well as any additional fees required, or to credit any overpayment to Deposit Account No.  
16-1445.

Respectfully submitted,

Date: May 24, 2007

/Pamela G. Salkeld/  
Pamela G. Salkeld  
Attorney for Applicant(s)  
Reg. No. 38,607

Pfizer, Inc.  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212) 733-2122